Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568038 | 0.86 | DAO (0.53) | KDM4ECYP1A2CYP2A6SYKMAPT | |
| SCHEMBL21214072 | 0.84 | GAA (0.42) | KDM4ECYP2A6SYKMAPTALDH1A1 | |
| SCHEMBL16382897 | 0.84 | SYK (0.53) | KDM4ESYKMAPTALDH1A1MEN1 | |
| SCHEMBL8999779 | 0.79 | MAPT (0.57) | KDM4ECYP2A6MAPTALDH1A1MEN1 | |
| SCHEMBL14706509 | 0.76 | SYK (0.39) | CYP2A6SYKMAPTALDH1A1KIF11 | |
| SCHEMBL23153302 | 0.76 | CYP1A1 (0.39) | KDM4ESYKMAPTALDH1A1DAO | |
| SCHEMBL1102337 | 0.76 | LOXL2 (0.50) | KDM4ECYP1A2CYP2A6MAPTALDH1A1 | |
| SCHEMBL31276626 | 0.76 | KIF11 (0.46) | CYP2A6SYKALDH1A1KIF11CFTR | |
| SCHEMBL3434958 | 0.76 | KIF11 (0.46) | CYP2A6SYKALDH1A1KIF11CFTR | |
| SCHEMBL13923569 | 0.76 | LOXL2 (0.50) | KDM4ECYP1A2MAPTALDH1A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-10472391-B2 | Methods and compositions using ADAM10 inhibitors to treat bacterial infections | THE UNIVERSITY OF CHICAGO (US) | 2019-11-12 | — | — | US | disclosed |
| EP-2888251-B1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INST (AU) | 2019-04-24 | — | — | EP | disclosed |
| US-20170143852-A1 | LIBRARY OF PH RESPONSIVE POLYMERS AND NANOPROBES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-05-25 | — | — | US | disclosed |
| US-9624211-B2 | Anti-cancer compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-18 | — | — | US | disclosed |
| US-8952049-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-10 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110071206-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110060024-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20100292466-A1 | Efficient Synthesis Of Galanthamine | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM | 2010-11-18 | — | — | US | disclosed |
| US-20100292489-A1 | Cross-conjugated 2,5-cyclohexadienone and related synthesis methods | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-11-18 | — | — | US | disclosed |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100048887-A1 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-7645789-B2 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292466-A1 | Efficient Synthesis Of Galanthamine | GALR2, GALR1, OPRK1 | KDM4E 628/4885CYP1A2 140/4885CYP2A6 270/4885 |
| US-20100292489-A1 | Cross-conjugated 2,5-cyclohexadienone and related synthesis methods | OPRK1, GALR2, OPRM1 | KDM4E 1151/4885CYP1A2 21/4885CYP2A6 61/4885 |
| US-20110071206-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885CYP1A2 2202/4885CYP2A6 1094/4885 |
| US-10472391-B2 | Methods and compositions using ADAM10 inhibitors to treat bacterial infections | ADAM10, ADAM17, ADAM9 | KDM4E 2633/4885CYP1A2 4139/4885CYP2A6 3806/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | KDM4E 1496/4885CYP1A2 398/4885CYP2A6 251/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | KDM4E 692/4885CYP1A2 1906/4885CYP2A6 903/4885 |
| US-20170143852-A1 | LIBRARY OF PH RESPONSIVE POLYMERS AND NANOPROBES THEREOF | MSN, CD44, CD47 | KDM4E 3295/4885CYP1A2 4855/4885CYP2A6 4149/4885 |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | CFTR, ABCB1, ABCB11 | KDM4E 3861/4885CYP1A2 1231/4885CYP2A6 1353/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KDM4E 1193/4885CYP1A2 205/4885CYP2A6 283/4885 |
| US-20100048887-A1 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE | PTGES, PTGS1, PTGES2 | KDM4E 2975/4885CYP1A2 67/4885CYP2A6 152/4885 |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | KDM4E 2822/4885CYP1A2 547/4885CYP2A6 934/4885 |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | KDM4E 4859/4885CYP1A2 4715/4885CYP2A6 4111/4885 |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885CYP1A2 2202/4885CYP2A6 1094/4885 |
| US-20110060024-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885CYP1A2 2202/4885CYP2A6 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.